Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
SAN DIEGO, May 31, 2017 -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company's participation at the Jefferies 2017 Global Healthcare Conference to be held in New York City from June 6 - 9, 2017.
The aTyr management team will present an overview of the Company during a presentation at 2:00 p.m. ET on Friday, June 9, 2017. The presentation will be webcast live through the "Investors" section of the aTyr Pharma website at www.atyrpharma.com. An audio replay will be available for at least 30 days following the initial presentation webcast.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological pathways. To date, the Company has generated three innovative therapeutic candidate programs based on its knowledge of Physiocrine biology in three different therapeutic areas. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 190 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential Physiocrine-based protein compositions. aTyr's key programs are currently focused on severe, rare diseases characterized by immune imbalance for which there are currently limited or no treatment options. For more information, please visit http://www.atyrpharma.com.
Contact: Mark Johnson Sr. Director, Investor Relations [email protected] 858-223-1163
